📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

P13K and T Lymphocyte development

Lead Research Organisation: Babraham Institute
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

T lymphocytes, so-called because they develop in the Thymus, are a type of white blood cell crucial for the function of the immune system. Aberrant function of these cells is associated with immunodeficiency (e.g. AIDS) or autoimmunity (e.g. Type I diabetes, rheumatioid arthritis). T lymphocytes are derived from blood stem cells and complete their maturation in the thymus, an organ located near the heart that has evolved specifically to provide an environment that promotes T cell development. The developmental stages haematopoietic (blood cell forming) stem cells pass through as they mature into T lymphocytes have been relatively well-characterised. This has allowed the identification of key regulatory checkpoints that cells must pass through in order to develop further. One of these checkpoints is called beta-selection. In order to pass through this checkpoint cells must generate specific signals which bring about changes in gene expression (the copying of DNA information into RNA) and allows the cells to divide. The beta-selection signal is also necessary for cells to survive. We have identified some of the genes which are responsible for generating the beta-selection signal. These genes which are called phosphatidylinositol-3- kinases are potential drug targets which are being actively investigated by many biotechnology and pharmaceutical companies.

Planned Impact

unavailable

Publications

10 25 50